trending Market Intelligence /marketintelligence/en/news-insights/trending/C-Y5AVqP00jVqab1gWptXg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Belgium's UCB to build €300M manufacturing facility, hire 150 employees

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Belgium's UCB to build €300M manufacturing facility, hire 150 employees

UCB SA said it will build a €300-million manufacturing unit in Belgium and hire about 150 employees for it.

The Brussels-based pharmaceutical company said it expects the multi-product biological manufacturing facility to be operational by 2024.

The unit will be constructed at Braine l'Alleud in Wallonia, Belgium, UCB added.

"The shift of our pipeline towards large molecules requires us to ramp up investment in mammalian technical development, as well as our manufacturing capabilities," UCB executive vice president Kirsten Lund-Jurgensen said in a statement.

Earlier this year, UCB entered an agreement to acquire autoimmune disease therapy developer Ra Pharmaceuticals Inc. in a $2.1-billion deal which is expected to close by the end of the first quarter of 2020.